image: Step into the future of pharmaceutical innovation with Insilico
Credit: Insilico Medicine
The topics of human-level artificial general intelligence (AGI) and artificial superintelligence (ASI) have captivated researchers for decades. Interest has surged with the rapid progress and deployment of large language models (LLMs), which now handle tasks such as coding, scientific explanation, creative writing, and multimodal reasoning. “Solve AI and it will solve everything” remains a popular, if contested, credo—driving large-scale investment, shaping public narratives, and motivating optimism about transformative advances.
Applying this vision to the healthcare and pharmaceutical industries, Insilico Medicine—a leading generative AI-driven drug discovery company — defines the pharmaceutical superintelligence (PSI) as the next step of AI-driven drug discovery, it showcases a fully-autonomous platform capable of discovering and designing a perfect small molecule or a biologic drug, together with the biomarker for patient selection, producing a significant disease-modifying or curative response for any disease without failure and without the need for further human experimentation.
Working toward this ultimate goal, Insilico continuously upgrades its Pharma.AI platform by integrating state-of-the-art algorithms, expanding and refining its data sources, and validating its models in real-world case studies. Recently, Insilico announced the final 2025 edition of its Pharma.AI Updates, scheduled for December 10, 2025, from 10:00 to 11:00 a.m. ET. This webinar will provide an in-depth look at major updates across key applications, including PandaOmics, Generative Biologics, Chemistry42, and Science42: DORA, through interactive demos and real-world case studies.
This major upgrade focuses on enhancing scientific rigor, enterprise-grade security, user experience, and a deeper, more mechanistic understanding of biology and chemistry, which is towards Pharmaceutical Superintelligence.
Key Highlights Include:
-
Generative Biologics applies physics-driven precision to binder design with automated molecular dynamics simulations, advanced scoring function, and interactive contact analysis.
-
Chemistry42 strengthens its analytical tools lineup with the upcoming features including MolSpace for versatile chemical space exploration and PACE for patent analysis.
-
PandaOmics for Target and Biomarker Discovery: More secure, more user‑friendly, and scientifically more advanced.
-
DORA for scientific content drafting: Developed with strong partners to support open‑source code preparation and analysis workflows.
-
MMAI Gym for Science: Dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10× performance gains on key drug discovery benchmarks
"Every upgrade of Pharma.AI marks a pivotal step in our mission to build a truly end-to-end biological and chemistry intelligence innovation loop," said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. "By being the first in the industry to introduce AI Gym for general-purpose LLMs, delivering advanced modules in Chemistry 42 and rolling out critical enhancements to PandaOmics, Generative Biologics, and DORA, we are providing our partners with an unparalleled ability to navigate complex biological and chemical data, de-risk their programs earlier, and ultimately accelerate the entire discovery process."
Register now to join Insilico's upcoming Pharma.AI Quarterly Launch Webinar: Q4 Winter Edition to get an exclusive look at the latest breakthroughs, game-changing updates, and future-shaping innovations across Pharma.AI.
In 2016, Insilico first described the concept of using generative AI for designing novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since then, Insilico has kept integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning biology, chemistry, medicine development, and science research. Powered by Pharma.AI, Insilico has nominated over 20 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of more than 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated a significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-edge automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across various industries, including advanced materials, agriculture, nutritional products, and veterinary medicine.
For more information, please visit www.insilico.com.